 |
41 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- | robatumumab (SCH 717454) / Merck (MSD)
Journal: A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. (Pubmed Central) - Jun 25, 2017
P2
These findings show that although the IGF-1R remains an attractive treatment target, additional research is needed to identify responders and/or means to achieve durable remissions in order to successfully exploit IGF-1R signal blockade in Ewing sarcoma (clinicaltrials.gov: NCT00617890).
- | robatumumab (SCH 717454) / Merck (MSD)
Trial termination: A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) (clinicaltrials.gov) - Sep 12, 2013
P2, N=219, Terminated, Sponsor: Merck Sharp & Dohme Corp.
These findings show that although the IGF-1R remains an attractive treatment target, additional research is needed to identify responders and/or means to achieve durable remissions in order to successfully exploit IGF-1R signal blockade in Ewing sarcoma (clinicaltrials.gov: NCT00617890). Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern.
- robatumumab (SCH 717454) / Merck (MSD)
Trial termination, Combination therapy, Metastases: A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) (clinicaltrials.gov) - Feb 20, 2012
P1, N=4, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern. Completed --> Terminated; Study was terminated for business reasons.
- robatumumab (SCH 717454) / Merck (MSD)
Trial termination: Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) (clinicaltrials.gov) - Feb 20, 2012
P1b/2, N=15, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Study was terminated for business reasons. Completed --> Terminated; This study was terminated for business reasons.